Kestra Medical Technologies (NASDAQ:KMTS) Reaches New 1-Year High – Time to Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s stock price reached a new 52-week high during trading on Wednesday. The company traded as high as $31.99 and last traded at $31.63, with a volume of 519,473 shares traded. The stock had previously closed at $29.55.

Wall Street Analyst Weigh In

KMTS has been the topic of several research reports. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Oppenheimer initiated coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday. Royal Bank Of Canada set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

Kestra Medical Technologies Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The company has a 50-day simple moving average of $27.13 and a two-hundred day simple moving average of $24.05. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -11.85 and a beta of 0.45.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The firm had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. On average, equities research analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current year.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Traci Umberger sold 30,000 shares of the business’s stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $30.03, for a total transaction of $900,900.00. Following the completion of the transaction, the insider directly owned 195,825 shares of the company’s stock, valued at $5,880,624.75. The trade was a 13.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Timothy Moran sold 3,192 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $29.56, for a total transaction of $94,355.52. Following the completion of the transaction, the insider owned 63,153 shares of the company’s stock, valued at approximately $1,866,802.68. This trade represents a 4.81% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 266,456 shares of company stock worth $7,585,946 over the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sei Investments Co. grew its holdings in Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after buying an additional 43,753 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Kestra Medical Technologies by 6.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after acquiring an additional 5,731 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after acquiring an additional 22,471 shares in the last quarter. Corient Private Wealth LP boosted its position in Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after acquiring an additional 44,839 shares during the period. Finally, Spartan Wealth Advisory Services LLC acquired a new position in Kestra Medical Technologies during the 1st quarter worth $603,000.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company’s flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient’s heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.